Study: Medical Marijuana Eases Symptoms for 80% of Cancer Patients

September 29, 2026

Photo by National Cancer Institute via Unsplash.

Two separate data sets landed within days of each other this fall, both pointing at the same basic idea from different directions: cancer patients who use marijuana, prescribed or not, tend to report feeling better across a whole range of symptoms. The headline number comes from a Kentucky study published in The Oncologist, where 80% of cannabis-using cancer patients surveyed said the plant helped their symptoms. That's a striking figure, but it's drawn from a relatively small, single-state sample of people undergoing radiation therapy. Around the same time, Minnesota's Office of Cannabis Management released findings from its state medical cannabis program covering more than 6,600 patients tracked over eight years, and it found a more modest but still meaningful improvement rate. Neither study is a randomized clinical trial, and neither should be read as a green light to skip conversations with an oncologist. But taken together, they add real weight to a pattern researchers have been circling for years.

Inside the Kentucky Study

Photo by Jo McNamara via Pexels.

The Kentucky research, published September 22, 2026 in The Oncologist, comes out of the University of Kentucky and its Markey Cancer Center, and it's built around survey responses from 237 adults undergoing radiation therapy. Participants were drawn from two very different settings: an urban radiation oncology practice and a rural satellite clinic, which matters because Kentucky's cannabis and drug-use landscape doesn't look like California's or Colorado's.

The researchers themselves describe Kentucky as a geographically and culturally distinct region marked by high endemic use of narcotics, a framing that shapes how they interpret cannabis use among cancer patients there. In a state where opioid use has been a persistent public health crisis, patients reaching for marijuana instead of, or alongside, prescribed narcotics is a different story than it would be in a state with a mature legal cannabis market and years of dispensary access.

To get at this, the team tracked marijuana use both before and after a cancer diagnosis, and asked patients specifically which symptoms they were trying to manage. The list of symptoms researchers focused on reads like a standard oncology quality-of-life checklist: pain, nausea, anxiety, depression, poor appetite and sleep disturbance. These are the symptoms that often persist through and after radiation treatment regardless of whether the underlying cancer responds well to therapy, and they're also the symptoms patients most commonly say cannabis helps with in surveys going back over a decade.

What the Numbers Actually Show

Among 237 Kentucky cancer patients, half (51%) reported ever using unprescribed cannabis, while smaller shares reported recent use specifically after (14.7%) or before (12.7%) their cancer diagnosis.

Once you get past the headline, the actual numbers are more nuanced than a simple 80% success rate. Of the 237 participants, 121 -- just over half, at 51% -- said they had used marijuana for medicinal purposes without a prescription at some point in their lives. That's a striking baseline on its own, suggesting unprescribed cannabis use is common among cancer patients in this population regardless of whether it's tied directly to their diagnosis.

Narrowing further, 35 patients (14.7%) reported recent marijuana use after their cancer diagnosis, compared with 30 patients (12.7%) who reported recent use before diagnosis. That's a modest uptick, not a dramatic shift, which suggests a diagnosis nudges some patients toward cannabis but doesn't send everyone running for it. The paper's own language is worth noting here: self-administration of unprescribed medicinal cannabis was common across demographic groups and primarily directed at symptom management, not recreational use.

The now-famous 80% figure applies specifically to cannabis users who answered the relevant survey questions about relief, not to all 237 patients in the study. That's an important distinction, since it's easy to see a headline like this and assume it describes the whole cancer patient population, when it actually describes a self-selected subgroup who were already using cannabis and chose to answer questions about how well it worked. An earlier, preliminary version of this research presented at ASTRO's 2024 annual meeting involved 200 participants, with 85% of active users reporting improved quality of life -- a number that shifted slightly as the sample grew to its final 237.

Why This Is Observational, Not Proof

Photo by RDNE Stock project via Pexels.

None of this makes the Kentucky findings meaningless, but it does mean they need to be read with some caution. The data comes entirely from self-reported patient surveys -- there was no lab testing, no verification of what product patients actually used, what dose, or how often. Patients were simply asked to recall and report their own experience, which introduces plenty of room for memory bias and inconsistent reporting of what counts as marijuana use in the first place.

This is observational research, and that distinction matters a lot. Observational studies can show an association between two things -- cannabis use and reported symptom relief, in this case -- but they can't establish that the cannabis actually caused the improvement. There was no control group and no randomization, so the researchers can't rule out a placebo effect, expectation bias, or the possibility that other treatments happening at the same time were doing the real work.

The researchers themselves are careful not to overstate their findings. They frame the study as documenting patterns of unprescribed cannabis use among cancer patients, not as clinical guidance on dosing, product selection or treatment protocols. That's a meaningful line to draw, because it's easy for a study like this to get picked up and repackaged online as proof that cannabis treats cancer symptoms, when what it actually shows is that a lot of patients are trying it on their own and reporting they feel it helps.

Given the lack of oversight around dosing and potential drug interactions, cancer patients considering cannabis alongside radiation or chemotherapy should loop in their oncology team first. Interactions with other medications, timing around treatment, and legal status all vary significantly by state, and a conversation with a provider beats guesswork.

A Bigger Data Point From Minnesota

Photo by Terrance Barksdale via Pexels.

While the Kentucky study was making headlines for its 80% figure, Minnesota's Office of Cannabis Management quietly released a much larger analysis in mid-to-late September 2026, looking at 6,621 patients enrolled in the state's medical cannabis program between July 2015 and December 2023. That's a dataset spanning nearly a decade, built on formal program enrollment rather than off-the-books use.

The Minnesota study found that roughly half of enrolled patients reported improvements in pain, nausea, appetite and mental health -- lower than Kentucky's number, but still a substantial majority-adjacent figure across a population more than 25 times the size of the Kentucky sample. Minnesota's medical cannabis program itself has grown considerably, now counting more than 90,000 registered patients statewide, with enrollment roughly doubling in recent years as more qualifying conditions were added and awareness spread.

The gap between Minnesota's roughly 50% and Kentucky's 80% is worth sitting with rather than dismissing. Minnesota's numbers come from patients formally enrolled in a regulated state program, working with registered products and presumably some level of guidance from program-affiliated pharmacists. Kentucky's figure comes from patients using cannabis without a prescription, often sourced informally, in a state where legal medical cannabis access has only recently started coming online. Different populations, different legal frameworks, different product quality controls -- yet both point toward a real, if variably sized, symptom-relief signal. That consistency across such different settings is arguably more persuasive than either number alone.

What It Means for Patients and Policy

Photo by Kindel Media via Pexels.

Stack these two studies next to the broader research landscape and you get a pattern that's been building for years: cannabis keeps showing up as a tool cancer patients reach for to manage the grinding, everyday symptoms of treatment, even when it isn't formally prescribed or tracked by their care team. That's a meaningful data point for oncology practices trying to understand what their patients are actually doing outside the clinic.

It's worth repeating that medical marijuana legality, qualifying conditions and access rules differ substantially from state to state and country to country. A patient in Kentucky navigating a limited or newly-launched program faces a very different legal reality than a patient in Minnesota with nearly a decade-old formal system, or a patient in a state where cannabis remains fully illegal. Anyone considering this route should check current local law rather than assume access or legality based on national headlines.

The high rate of unprescribed use found in Kentucky -- over half of patients having tried cannabis medicinally at some point -- raises a real question that goes beyond whether cannabis works: are patients self-medicating without any dosing guidance, quality control, or awareness of interactions with their cancer treatment? That's a safety and oversight issue independent of whether cannabis provides genuine relief.

Expect both studies to get cited in ongoing policy fights over cannabis rescheduling and expanded medical access for cancer patients specifically, since oncology has long been one of the more sympathetic use cases in the broader legalization debate. But researchers on both teams would likely agree that getting from these results to established clinical practice requires larger, controlled studies -- the kind with randomization, verified dosing and comparison groups -- that neither Kentucky nor Minnesota has produced yet.

What both studies really capture is a gap between what's happening in exam rooms and what's been formally tested in a lab. Patients are already using cannabis, prescribed or otherwise, to get through radiation and chemotherapy, and a large share of them say it helps. That's useful information for oncologists trying to understand their patients' full picture of self-care, but it isn't the kind of evidence that produces a dosing chart or a standardized treatment protocol.

Until someone runs the kind of large, randomized, controlled trial that could actually isolate cannabis's effect from placebo, expectation and concurrent treatment, patients and their doctors are stuck working with what's available: observational surveys, state program data, and a legal landscape that shifts depending on which state line you're standing on. That's not a satisfying place to land if you're a cancer patient trying to decide whether to try cannabis for your nausea or sleep problems, but it's the honest state of the evidence right now -- promising, consistent across very different populations, and still a long way from settled science.